X

Trial Profile

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 30 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adavosertib (Primary) ; Capivasertib (Primary) ; Ceralasertib (Primary) ; Olaparib (Primary)
Indications Cholangiocarcinoma; Solid tumours
Focus Therapeutic Use
Acronyms OLAPCO

Most Recent Events

29 Dec 2022 Status changed from active, no longer recruiting to discontinued.
14 Sep 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
14 Sep 2021 Planned primary completion date changed from 1 Aug 2021 to 1 Aug 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com